GLP1R and type 2 diabetes mellitus: Semaglutide, also known as Ozempic or Wegovy, is a GLP-1 analog approved for the treatment of T2DM, cardiovascular risk reduction in patients with T2DM, and treatment of obesity [50-59]. Studies are being done on tirzepatide for similar claims.